natgillin/translations-raw huggingface dataset:
The response rate to topotecan in the combined small cell lung cancer programme (n = 480) for patients with relapsed disease sensitive to first-line therapy was 20.2%. 
Odstotek odziva na topotekan po združenih podatkih programa zdravljenja drobnoceličnega pljučnega raka (n = 480) pri bolnikih s ponovitvijo bolezni, ki je bila dovzetna za zdravljenje prve linije, je bil 20,2 %.
If you get the capsule contents in your eyes, wash them immediately with gently flowing water for at least 15 minutes. 
Če zdravilo pride v oči, morate oči takoj vsaj 15 minut izpirati z vodo, ki ne teče premočno.
The hazard ratio for survival with IV topotecan relative to CAV was 1.04 (95% CI: 0.78, 1.40). 
Razmerje ogroženosti za preživetje z intravenskim topotekanom relativno glede na kombinacijo CAV je bilo 1,04 (95-odstotni IZ: 0,78, 1,40).
As with other cytotoxic medicinal products, topotecan may cause foetal harm and therefore women of childbearing potential should be advised to avoid becoming pregnant during therapy with topotecan. 
Tako kot druga citotoksična zdravila lahko tudi topotekan škoduje plodu, zato je ženske v rodni dobi potrebno opozoriti, da med zdravljenjem s topotekanom ne smejo zanositi.
Therefore, use of the normal starting dose in patients with a mild decrease in renal function is considered established (see section 4.2). 
Zato velja, da je uporaba normalnega začetnega odmerka pri bolnikih z blago ledvično okvaro ustrezno utemeljena (glejte poglavje 4.2).
If, during topotecan/cisplatin combination therapy, serum creatinine exceeds 1.5 mg/dl, it is recommended that the full prescribing information be consulted for any advice on cisplatin dose reduction/continuation. 
Če med zdravljenjem s kombinacijo topotekan/cisplatin vrednost kreatinina v serumu preseže 1,5 mg/dl, je priporočljivo pregledati navodila za predpisovanje cisplatina glede kakršnegakoli navodila glede zmanjšanja odmerka cisplatina ali nadaljevanja zdravljenja.
The dose of Hycamtin you are given will be worked out by your doctor, based on: 
Odmerek zdravila Hycamtin, ki ga boste prejeli, bo zdravnik določil glede na:
However, when combining with platinum agents, there is a distinct sequence-dependent interaction depending on whether the platinum agent is given on day 1 or 5 of the topotecan dosing. 
Pri sočasni uporabi s platinovimi spojinami pride do izrazite interakcije, ki je odvisna od zaporedja dajanja zdravil, in sicer od tega, ali bolnik prejme zdravilo s platino na 1. ali 5. dan dajanja topotekana.
Moderate to severe anaemia (Grade 3 and 4 - Hb 8.0 g/dl) occurred in 25% of patients (12% of courses). 
Zmerna do huda anemija (3. in 4. stopnje - Hb 8,0 g/dl) se je pojavila pri 25 % bolnikov (v 12 % ciklusov).
If well tolerated, the dose may be increased to 2.3 mg/m 2/day in subsequent cycles (see section 5.2). 
Če zdravilo bolnik dobro prenaša, je mogoče v naslednjih ciklusih odmerek povečati na 2,3 mg/m telesne površine na dan (glejte poglavje 5.2).
In clinical studies, rash was reported in 4% of patients and pruritus in 1.5% of patients. 
V kliničnih študijah so o izpuščaju poročali pri 4 % bolnikov, o srbenju pa pri 1,5 % bolnikov.
Complete alopecia related/possibly related to topotecan administration was observed in 9% of patients and partial alopecia related/possibly related to topotecan administration in 11% of patients. 
Popolno alopecijo, povezano ali morda povezano z uporabo topotekana, so zabeležili pri 9 % bolnikov, delno alopecijo, povezano ali morda povezano z uporabo topotekana, pa pri 11 %.
Topotecan monotherapy is indicated for the treatment of: 
Samostojno zdravljenje s topotekanom je indicirano pri:
• Weight loss and loss of appetite (anorexia); tiredness; weakness. 
• hujšanje in neješčnost (anoreksija), utrujenost, šibkost;
Hycamtin is used to treat: 
Zdravilo Hycamtin uporabljamo za zdravljenje:
• Pregnant staff should be excluded from working with this medicinal product. 
• Nosečnice ne smejo rokovati z zdravilom.
Infections and infestations Very common Infection Common 
Infekcijske in parazitske bolezni zelo pogosti okužba pogosti sepsa
Other severe events that were recorded as related or possibly related to topotecan treatment were anorexia (12%), malaise (3%) and hyperbilirubinaemia (1%). 
Drugi močno izraženi neželeni dogodki, ki so jih ocenili kot posledico ali možno posledico zdravljenja s topotekanom, so bili anoreksija (12 %), splošno slabo počutje (3 %) in hiperbilirubinemija (1 %).
In vitro, topotecan did not inhibit human P450 enzymes CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A or CYP4A, nor did it inhibit the human cytosolic enzymes dihydropyrimidine or xanthine oxidase. 
Topotekan in vitro pri človeku ni zaviral delovanja encimov P450 (CYP1A2, CYP2A6, CYP2C8/9, CYP2C19, CYP2D6, CYP2E, CYP3A ali CYP4A).
Overall recovery of topotecan-related material following five daily doses of topotecan was 71 to 76% of the administered IV dose. 
Celokupno izločanje s topotekanom povezanih snovi po petih dnevnih odmerkih topotekana je bilo od 71 do 76 % intravensko prejetega odmerka.
In clinical studies with topotecan in combination with cisplatin for the treatment of cervical cancer, therapy was only initiated in patients with serum creatinine less than or equal to 1.5 mg/dl. 
Med kliničnimi študijami zdravljenja raka materničnega vratu je bilo zdravljenje s topotekanom v kombinaciji s cisplatinom uvedeno le pri bolnicah, ki so imele vrednost kreatinina v serumu manjšo ali enako 1,5 mg/dl.
• patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1). 
• bolnikih s ponovitvijo drobnoceličnega pljučnega raka, pri katerih ponovno zdravljenje s terapijo prve linije ni primerno (glejte poglavje 5.1).
Hycamtin is used to treat small cell lung cancer that has come back after chemotherapy. 
Zdravilo Hycamtin uporabljamo za zdravljenje drobnoceličnega pljučnega raka, ki se je ponovil po kemoterapiji.
Pancytopenia has been reported. 
Poročali so o pancitopeniji.
Preclinical studies indicate plasma protein binding of topotecan is low (35%) and distribution between blood cells and plasma was fairly homogeneous. 
Predklinične študije kažejo, da se topotekan le malo veže na beljakovine v plazmi (35 %), precej enakomerno pa se razporedi med krvnimi celicami in plazmo.
Severe neutropenia lasted beyond seven days in 11% of courses overall. 
Huda nevtropenija je pri 11 % vseh ciklusov zdravljenja trajala več kot sedem dni.
Median time to progression was similar in the two groups (13.3 weeks and 12.3 weeks, respectively). 
Mediana časa do napredovanja je bila v obeh skupinah podobna, in sicer pri topotekanu 13,3 tedna, pri kombinaciji CAV pa 12,3 tedna.
When combining topotecan with other chemotherapy agents, reduction of the doses of each medicinal product may be required to improve tolerability. 
Pri sočasni uporabi topotekana z drugimi kemoterapevtiki je morda zaradi boljšega prenašanja potrebno zmanjšati odmerek vsakega zdravila.
All items for administration or cleaning, including gloves, should be placed in high-risk, waste disposal bags for high-temperature incineration. 
- Vse pripomočke, ki jih potrebujete pri dajanju zdravila ali čiščenju, tudi rokavice, je treba odvreči v vreče za shranjevanje nevarnih odpadkov, ki so namenjene sežigu pri visokih temperaturah.
Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic material. 
Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi za citotoksične snovi.
In addition, elevated hepatic enzymes have been reported with intravenous topotecan overdose. 
Poleg tega so poročali o povišanih vrednostih jetrnih encimov v primeru prevelikega odmerjanja z intravenskim topotekanom.
Topotecan inhibits topoisomerase-I by stabilising the covalent complex of enzyme and strand-cleaved DNA which is an intermediate of the catalytic mechanism. 
Topotekan zavira topoizomerazo I tako, da stabilizira kovalentni kompleks tega encima in enojne verige DNA, ki je vmesni produkt katalitičnega mehanizma.
Dosing recommendations for patients receiving oral topotecan with creatinine clearance less than 30 ml/min have not been established. 
Priporočila za odmerjanje peroralnega topotekana pri bolnikih z očistkom kreatinina pod 30 ml/min niso določena.
In vitro data using human liver microsomes indicate the formation of small amounts of Ndemethylated topotecan. 
V raziskavi in vitro, v kateri so uporabili mikrosome človeških jeter, so opazili nastanek majhne količine N-demetiliranega topotekana.
In an open-label study involving children (n = 108, age range: infant to 16 years) with recurrent or progressive solid tumours, topotecan was administered at a starting dose of 2.0 mg/m given as a 
V odprti študiji pri otrocih (n = 108, razpon starosti: od dojenčka do 16 let) z rekurentnim ali progresivnim solidnim tumorjem so otroci topotekan prejemali v začetnem odmerku 2,0 mg/m v obliki 30-minutne infuzije 5 dni.
Inhibitors of ABCB1 and ABCG2 administered with oral topotecan have been shown to increase topotecan exposure. 
Sočasna uporaba zaviralcev ABCB1 in ABCG2 ter peroralnega topotekana poveča izpostavljenost topotekanu.
However, as with other cytotoxic medicinal products, topotecan is genotoxic and effects on fertility, including male fertility, cannot be excluded. 
Ker pa je topotekan - tako kot druga citotoksična zdravilagenotoksičen, ni mogoče izključiti učinkov na plodnost, vključno z učinki na plodnost samcev.
• Unusual bruising or bleeding, caused by a decrease in the number of clotting cells in the blood. 
• neobičajne modrice ali krvavitve, ki so posledica zmanjšanega števila trombocitov, ki zagotavljajo strjevanje krvi.
There is no known antidote for topotecan overdose. 
Antidot za preveliko odmerjanje s topotekanom ni znan.
For severe cases (CTC Grade 3/4) reported as related/possibly related to topotecan administration the incidence was diarrhoea 5% (see section 4.4), fatigue 4%, vomiting 3%, nausea 3% and anorexia 2%. 
Incidenca hudih primerov (3. in 4. stopnja po CTC), ki so bili opisani kot povezani ali morda povezani z uporabo topotekana, je bila: driska 5 % (glejte poglavje 4.4), utrujenost 4 %, bruhanje 3 %, navzea 3 % in anoreksija 2 %.
Growth factors were administered to 19% of patients in 8% of courses. 
Rastne dejavnike so uporabili pri 19 % bolnikov v 8 % ciklusov.
Communication with patients prior to drug administration regarding these side effects and proactive management of early and all signs and symptoms of diarrhoea is important. 
Pomembno je takojšnje ukrepanje v primeru zgodnjih in vseh znakov in simptomov driske.
• Accidental contact with the skin or eyes should be treated immediately with copious amounts of water. 
• Ob naključnem stiku zdravila s kožo ali z očmi jih morate takoj sprati z veliko količino vode.
Signs include: fever serious deterioration of your general condition local symptoms such as sore throat or urinary problems (for example, a burning sensation when urinating, which may be a urinary infection). 
Med znaki so: zvišana telesna temperatura, resno poslabšanje splošnega zdravstvenega stanja, lokalni simptomi, npr. vnetje žrela ali težave s sečili (npr. pekoč občutek pri uriniranju, ki je lahko znak okužbe sečil).
The use of topotecan should be confined to units specialised in the administration of cytotoxic chemotherapy. 
Topotekan se sme uporabljati le v ustanovah, ki so specializirane za uporabo citotoksičnih kemoterapevtikov.
9/l) in 25% of patients (8% of courses); moderate (platelets between 25.0 and 
9/l) se je razvila pri 25 % bolnikov (v 8 % ciklusov zdravljenja), zmerna (število trombocitov med 25,0 in 50,0 x 10
Patients without prior cisplatin chemoradiotherapy Cisplatin Topotecan/Cisplatin 
Bolnice brez predhodne kemoterapije s cisplatinom cisplatin topotekan/cisplatin
Hycamtin 0.25 mg and 1 mg capsules are available in packs containing 10 capsules. 
0,25-miligramske in 1-miligramske kapsule zdravila Hycamtin so na voljo v pakiranjih, ki vsebujejo po 10 kapsul.
• High body temperature (fever). 
• zvišana telesna temperatura;
Therapeutic interventions associated with non-haematological effects included anti-emetic agents, given to 47% of patients in 38% of courses and anti-diarrhoeal agents, given to 15% of patients in 6% of courses. 
Med terapevtskimi ukrepi zaradi nehematoloških učinkov je bila uporaba antiemetikov (dobilo jih je 47 % bolnikov v 38 % ciklusov) in antidiaroikov (dobilo jih je 15 % bolnikov v 6 % ciklusov).
Skin and subcutaneous tissue disorders Very common Alopecia Common 
Bolezni kože in podkožja zelo pogosti alopecija pogosti srbenje
This can lead to severe bleeding from relatively small injuries such as a small cut. 
Že pri relativno blagi poškodbi, npr. manjši vreznini, se lahko pojavi obilna krvavitev.
In 18% of courses with severe thrombocytopenia the duration was >7 days. 
V 18 % ciklusov s hudo trombocitopenijo je ta trajala >7 dni.
The adverse events listed above have the potential to occur with a higher frequency in patients who have a poor performance status (see section 4.4). 
Zgoraj navedeni neželeni dogodki so lahko pogostejši pri bolnikih s slabšo telesno zmogljivostjo (glejte poglavje 4.4).
In dose-finding studies involving 523 patients with relapsed ovarian cancer and 631 patients with relapsed small cell lung cancer, the dose-limiting toxicity of topotecan monotherapy was found to be haematological. 
V študijah za določitev ustreznega odmerka, v katere je bilo vključenih 523 bolnic s ponovitvijo raka na jajčniku in 631 bolnikov s ponovitvijo drobnoceličnega pljučnega raka, so ugotovili, da pri zdravljenju s topotekanom kot samostojnim zdravilom, odmerek omejuje hematološka toksičnost.
WARNING: Cytotoxic agents, special handling instructions (see Package Leaflet). 
OPOZORILO: Citotoksično zdravilo, posebna navodila za ravnanje (glejte Navodilo za uporabo).
Median survival (weeks) (95% CI) Hazard ratio (95% CI) Response rate (%) (95% CI) Difference in response rate (95% CI) Median time to progression (weeks) (95% CI) Hazard ratio (95% CI) N = total number of patients treated CI = confidence interval 
Mediano preživetje (tedni) (95-odstotni IZ) Razmerje tveganja (95-odstotni IZ) Delež odziva (%) (95-odstotni IZ) Razlika v deležu odziva (95-odstotni IZ) Mediani čas do napredovanja (tedni) (95-odstotni IZ) Razmerje tveganja (95-odstotni IZ) n = celotno število zdravljenih bolnikov IZ = interval zaupanja
In 34% of courses with severe neutropenia, the duration was >7 days. 
V 34 % ciklusov s hudo nevtropenijo je ta trajala >7 dni.
The pharmacokinetics of oral topotecan have not been studied in patients with hepatic impairment (see section 4.2 and 4.4). 
Farmakokinetika peroralnega topotekana ni raziskana pri bolnikih z okvaro jeter (glejte poglavji 4.2 in 4.4).
• Ovarian and small cell lung cancer: 1.5 mg per square metre of body surface area per day. 
• rak jajčnika in drobnocelični pljučni rak: 1,5 mg na kvadratni meter telesne površine na dan.
Patient self-reports of symptoms using an unblinded assessment showed a consistent trend for symptom benefit for oral topotecan plus BSC. 
Neslepljeno ocenjene navedbe bolnikov samih o simptomih so pokazale dosleden trend k boljšemu simptomatskemu stanju v skupini, zdravljeni s peroralnim topotekanom in NPO.
The unadjusted hazard ratio for the oral topotecan plus BSC group relative to the BSC alone group was 0.64 (95% CI: 0.45, 0.90). 
Nekorigirano razmerje ogroženosti med skupino s peroralnim topotekanom in NPO ter skupino s samo NPO je bilo 0,64 (95-odstotni IZ: 0,45, 0,90).
Diarrhoea related to oral topotecan can occur at the same time as drug-related neutropenia and its sequelae. 
Driska zaradi peroralnega topotekana se lahko pojavi hkrati z nevtropenijo, povezano s tem zdravilom, in njenimi posledicami.
• Swelling caused by fluid build-up (angioedema). 
• otekanje zaradi kopičenja tekočine (angioedem);
• Severe stomach pain, nausea, vomiting of blood, black or bloody stools (possible symptoms of gastrointestinal perforation). 
• hude bolečine v trebuhu, občutek slabosti, bruhanje krvi, črno ali krvavo blato (to so lahko simptomi gastrointestinalne perforacije ali predrtja stene prebavil);
The mean metabolite: parent plasma AUC ratio was less than 10% for both total topotecan and topotecan lactone. 
Povprečno razmerje med AUC presnovka in matične snovi v plazmi je bilo manjše od 10 % tako za celotni topotekan kot za topotekanov lakton.
Median (95% CI) Hazard ratio (95% CI) Log rank p-value 
Mediana vrednost (95-odstotni IZ) Razmerje tveganja (95-odstotni IZ) Log rank p-vrednost
Moderate to severe (Hb 8.0 g/dl) in 37% of patients (14% of courses). 
Zmerna do huda oblika (Hb ≤8,0 g/dl) se je razvila pri 37 % bolnikov (v 14 % ciklusov zdravljenja).
The capsule(s) must be swallowed whole, and must not be chewed, crushed or divided. 
Kapsule morate pogoltniti cele in jih ne smete žvečiti, drobiti ali deliti.
Haematological toxicity is dose-related and full blood count including platelets should be determined regularly (see section 4.2). 
Hematološka toksičnost je odvisna od odmerka, zato je treba bolnikom redno pregledovati celotno krvno sliko, vključno s trombociti (glejte poglavje 4.2).
Moderate thrombocytopenia (Grade 3 - platelets between 10.0 and 50.0 x 10 
Zmerna trombocitopenija (3. stopnje - število trombocitov med 10,0 in 50,0 x 10
Topotecan is contraindicated during breast-feeding (see section 4.3). 
Topotekan je med dojenjem kontraindiciran (glejte poglavje 4.3).
Infection, sepsis and febrile neutropenia occurred in 17%, 2%, and 4% of patients, respectively. 
Okužbe so se pojavile pri 17 % bolnikov, sepsa pri 2 % in febrilna nevtropenija pri 4 %.
Cancer treatment-induced diarrhoea (CTID) is associated with significant morbidity and may be life-threatening. 
Drisko zaradi zdravil proti raku spremlja velika obolevnost in je lahko smrtno nevarna.
Plasma clearance in patients with hepatic impairment (serum bilirubin between 1.5 and 10 mg/dl) decreased to about 67% when compared with a control group of patients. 
Plazemski očistek pri bolnikih z jetrno okvaro (bilirubin v serumu med 1,5 in 10 mg/dl) se je v primerjavi s kontrolno skupino znižal na približno 67 %.
Side effects with frequency not known 
Neželeni učinki z neznano pogostnostjo
Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. 
Topotekan je v kombinaciji s cisplatinom indiciran pri bolnicah s ponovitvijo karcinoma materničnega vratu po zdravljenju z obsevanjem in bolnicah s stadijem IVB karcinoma materničnega vratu.
Hard capsule. 
trda kapsula
9/l) in 25% of patients (15% of courses). 
9/l) pa pri 25 % bolnikov (v 15 % ciklusov zdravljenja).
When topotecan is used in combination with cisplatin, the full prescribing information for cisplatin should be consulted. 
Pri uporabi topotekana v kombinaciji s cisplatinom je treba upoštevati tudi navodila za predpisovanje cisplatina.
Prior to administration of the first course of topotecan, patients must have a baseline neutrophil count of 1.5 x 10 
Pred prvim ciklusom zdravljenja s topotekanom morajo imeti bolniki izhodiščno število nevtrofilcev 1,5 x 10
Those effects are described in the cisplatin patient leaflet. 
Ti neželeni učinki so navedeni v navodilu za uporabo cisplatina.
Topotecan monotherapy and topotecan in combination with cisplatin are commonly associated with clinically relevant thrombocytopenia. 
Uporaba samega topotekana in topotekana v kombinaciji s cisplatinom je pogosto povezana s pojavljanjem klinično pomembne trombocitopenije.
VIAL 
VIALA
Patients with prior cisplatin chemoradiotherapy Cisplatin Topotecan/Cisplatin 
Bolnice s predhodno kemoterapijo s cisplatinom cisplatin topotekan/cisplatin
Peel back the outer layer: starting at the coloured corner, lift and peel over the pocket. 
Odlepite zadnjo plast: začnite na obarvanem vogalu ter jo dvignite in odlepite s celotnega žepa.
No in vivo human pharmacokinetic interaction studies have been performed. 
Farmakokinetičnih študij medsebojnega delovanja in vivo pri ljudeh niso izvedli.
Frequently reported non-haematological effects were gastrointestinal, such as nausea (52%), vomiting (32%), diarrhoea (18%), constipation (9%) and mucositis (14%). 
Pogostejši nehematološki učinki so bile gastrointestinalne težave, kot so navzea (52 %), bruhanje (32 %), driska (18 %), zaprtje (9 %) in vnetje ustne sluznice (14 %).
The pharmacokinetics of topotecan after oral administration have been evaluated in cancer patients following doses of 1.2 to 3.1 mg/m2/day and 4 mg/m2/day administered daily for 5 days. 
Farmakokinetiko peroralnega topotekana so ocenili pri bolnikih z rakom po odmerkih od 1,2 do 3,1 mg/m2/dan in 4 mg/m2/dan, uporabljenih vsak dan pet dni.
• patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. 
• bolnicah z rakom jajčnika z metastazami, če terapija prve linije in tudi naslednje terapije niso uspele,
If reconstitution is performed under strict aseptic conditions Hycamtin infusion may be completed within 12 hours at room temperature (or 24 hours if stored at 2-8oC). 
Če je priprava potekala v strogo aseptičnih pogojih, lahko infundiranje zdravila Hycamtin končate v 12 urah, če raztopino hranite pri sobni temperaturi (ali v 24 urah, če jo hranite pri temperaturi od 2 do 8 °C).
One study included a dose range of 1.4 to 2.4 mg/m in children (aged 2 up to 12 years, n = 18), adolescents (aged 12 up to 16 years, n = 9) and young adults (aged 16 to 21 years, n = 9) with refractory solid tumours. 
V eni študiji so otroci (stari od 2 do 12 let, n = 18), mladostniki (stari od 12 do 16 let, n = 9) in mlajši odrasli (stari od 16 do 21 let, n = 9) z neodzivnim solidnim tumorjem prejemali odmerek od 1,4 do 2,4 mg/m2.
Interstitial lung disease (some cases have been fatal) Gastrointestinal disorders Very common Nausea, vomiting and diarrhoea (all of which may be severe), which may lead to dehydration (see sections 4.2 and 4.4) 
Bolezni prebavil zelo pogosti navzea, bruhanje in driska (vse lahko v hudi obliki), ki lahko povzročijo dehidracijo (glejte poglavji 4.2 in 4.4)
Since the vial contains a 10% overage, the clear, reconstituted solution is yellow to yellow-green in colour and provides 1 mg of topotecan per ml. 
Ker viala vsebuje 10 % prebitka, je pripravljena bistra raztopina rumene do rumeno-zelene barve in vsebuje 1 mg topotekana na mililiter.
In a population study using the intravenous route, the co-administration of granisetron, ondansetron, morphine or corticosteroids did not appear to have a significant effect on the pharmacokinetics of total topotecan (active and inactive form). 
V populacijski študiji intravenske uporabe zdravila niso zasledili, da bi sočasno dajanje granisetrona, ondansetrona, morfina ali kortikosteroidov pomembneje vplivalo na farmakokinetiko celotnega topotekana (aktivne in neaktivne oblike).
The anti-tumour activity of topotecan involves the inhibition of topoisomerase-I, an enzyme intimately involved in DNA replication as it relieves the torsional strain introduced ahead of the moving replication fork. 
Protitumorsko delovanje topotekana vključuje zaviranje encima topoizomeraze I. Ta encim je tesno povezan s podvojevanjem DNA in odpravlja torzijsko napetost, ki se pojavlja pred napredujočimi replikacijskimi vilicami.
Relapsed ovarian cancer 
Ponovitev raka jajčnikov
White polyvinyl chloride / polychlorotrifluoroethylene blister sealed with aluminium / Polyethylenterephtalate (PET) / paper foil lidding. 
Bel pretisni omot iz polivinilklorida/poliklorotrifluoretilena z zaporno folijo iz aluminija/polietilentereftalata (PET)/papirja.
The contents of HYCAMTIN 1 mg vials must be reconstituted with 1.1 ml water for injections. 
Vsebino viale z zdravilom HYCAMTIN 1 mg je treba rekonstituirati z 1,1 ml vode za injekcije.
Reports of significant sequelae associated with thrombocytopenia including fatalities due to tumour bleeds have been infrequent. 
Poročila o resnih zapletih, povezanih s trombocitopenijo, vključno s smrtnimi primeri zaradi tumorske krvavitve, so bila redka.
Titanium dioxide (E171) Red iron oxide (E172) 
Ovojnica kapsule želatina titanov dioksid (E171) rdeči železov oksid (E172)